Please login to the form below
colorectal cancer
This page shows the latest colorectal cancer news and features for those working in and with pharma, biotech and healthcare.
Home-grown colorectal cancer drug approved in China
Home-grown colorectal cancer drug approved in China. Hutchison China MediTech (Chi-Med) has been granted approval in its home market for Elunate, the first drug discovered and developed in China ... for colorectal cancer (CRC).
Latest news
-
Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices
or mismatch repair deficient (dMMR) metastatic colorectal cancer. ... About 4% to 5% of metastatic colorectal cancer patients have those mutations, and make them less likely to benefit from conventional chemotherapy.
-
ACT immunotherapy cures terminal breast cancer patient
ACT immunotherapy cures terminal breast cancer patient. The new approach focuses on mutations rather than cancer type. ... The new study suggests that barrier could be overcome. Rosenberg says investigators have already tested the approach in liver and
-
Loxo, Bayer get quick FDA review for ‘precision’ cancer drug
biomarker, a departure from the usual regulatory route of seeking approval based on the organ or tissue where the cancer starts to grow. ... NTRK fusions are seen in a broad range of tumour types, including various forms of colorectal, lung, thyroid,
-
Another IO knockback as Tecentriq combo fails phase III trial
cancer (CRC) showed no benefit on overall survival compared to Bayer’s Stivarga (regorafenib), a drug typically used in that hard-to-treat population. ... In particular, we have a number of studies evaluating medicines in colorectal cancer that could
-
AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine
AstraZeneca’s PD-L1 inhibitor Imfinzi and Bavarian Nordic’s cancer vaccine CV301 will be combined in a phase I/II trial involving patients with metastatic colorectal or pancreatic cancers. ... Colorectal and pancreatic cancers are among the most
More from news
Approximately 18 fully matching, plus 230 partially matching documents found.
Latest Intelligence
-
Pharma deals continue to slide
CAP7.1 prodrug of etoposide at start phase 3 for second line treatment of biliary tract cancer. ... Phase III toll-like receptor 9 agonist for metastatic colorectal cancer. 124.
-
Winning the war against cancer
data sources and the organisation of screening programmes for colorectal cancer. ... Cancer is an important disease to see [its] impact on the health system.
-
Deal Watch September 2016
Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Janssen granted Tracon Pharmaceuticals the rights to
-
Pharma deals during February 2014
MK-3475 was awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. ... BATON studies in colorectal cancer and metastatic triple negative breast cancer.
-
The oncology market in Canada
on the other side of the border, three tumours have comparable incidence rates, while colorectal cancer is a distant number four. ... Colorectal cancer. Colorectal cancer is where the two countries demonstrate the most substantial differences.
More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
Kite Pharma appoints head of regulatory affairs
colorectal cancer. ... Other recent additions include chief financial officeras chief medical officer; and several cancer experts to the company's scientific advisory board.
-
Boston Biomedical appoints commercial head
colorectal cancer.
-
Mirna hires former Pfizer director as CMO
Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... This background will benefit Mirna, which has just
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
90TEN nominated for five Communiqué Awards
Meanwhile two of the agency’ s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated
-
Lynch syndrome: a patient perspective
My grandfather was probably the first in the family to be afflicted with Lynch syndrome or Hereditary Nonpolyposis Colorectal Cancer (HNPCC). ... A revolutionary discovery. For my father, the cancer came back four more times.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Associate Scientific Director
-
Salary TBC
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
-
Sudler London - Account Director
-
Competitive
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Account Director or Senior Account Director
-
Salary TBC
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Systematic Review Lead- London
-
Negotiable
- Sudler London - Senior Medical Writer
-
Competitive
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
Subscribe to our email news alerts
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Healthcircle
We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
